Indications
Treatment of osteoporosis: in post-menopausal women; in men; at increased risk of fracture including those with a recent low-trauma hip fracture. Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: in post-menopausal women; in men; at increased risk of fracture. Treatment of Paget’s disease of the bone in adults.
Composition
- Active substance
- zoledronic acid
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Zoledronic acid Teva Pharma
- Active substance
- zoledronic acid
- ATC code
- M05BA08
- Therapeutic area
- Osteoporosis, Osteitis Deformans, Osteoporosis, Postmenopausal